ABUS
Price:
$4.55
Market Cap:
$858.96M
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destab...[Read more]
Industry
Biotechnology
IPO Date
2007-07-26
Stock Exchange
NASDAQ
Ticker
ABUS
According to Arbutus Biopharma Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -10.11. This represents a change of 72.99% compared to the average of -5.84 of the last 4 quarters.
The mean historical PE Ratio of Arbutus Biopharma Corporation over the last ten years is -4.03. The current -10.11 PE Ratio has changed 24.98% with respect to the historical average. Over the past ten years (40 quarters), ABUS's PE Ratio was at its highest in in the June 2018 quarter at 32.60. The PE Ratio was at its lowest in in the December 2014 quarter at -18.55.
Average
-4.03
Median
-3.92
Minimum
-8.42
Maximum
-0.34
Discovering the peaks and valleys of Arbutus Biopharma Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 867.09%
Maximum Annual PE Ratio = -0.34
Minimum Annual Increase = -89.77%
Minimum Annual PE Ratio = -8.42
Year | PE Ratio | Change |
---|---|---|
2023 | -5.70 | 12.48% |
2022 | -5.06 | -5.23% |
2021 | -5.34 | 29.42% |
2020 | -4.13 | 299.84% |
2019 | -1.03 | -72.17% |
2018 | -3.71 | 13.35% |
2017 | -3.27 | 867.09% |
2016 | -0.34 | -89.77% |
2015 | -3.31 | -60.72% |
2014 | -8.42 | -2.74% |
The current PE Ratio of Arbutus Biopharma Corporation (ABUS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-5.37
5-year avg
-4.25
10-year avg
-4.03
Arbutus Biopharma Corporation’s PE Ratio is less than VBI Vaccines Inc. (-0.02), less than ADMA Biologics, Inc. (108.63), less than Adaptimmune Therapeutics plc (-3.82), less than Affimed N.V. (-0.66), greater than Corvus Pharmaceuticals, Inc. (-10.64),
Company | PE Ratio | Market cap |
---|---|---|
-0.02 | $1.87M | |
108.63 | $3.79B | |
-3.82 | $278.72M | |
-0.66 | $57.26M | |
-10.64 | $252.08M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arbutus Biopharma Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arbutus Biopharma Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arbutus Biopharma Corporation's PE Ratio?
How is the PE Ratio calculated for Arbutus Biopharma Corporation (ABUS)?
What is the highest PE Ratio for Arbutus Biopharma Corporation (ABUS)?
What is the 3-year average PE Ratio for Arbutus Biopharma Corporation (ABUS)?
What is the 5-year average PE Ratio for Arbutus Biopharma Corporation (ABUS)?
How does the current PE Ratio for Arbutus Biopharma Corporation (ABUS) compare to its historical average?